Search | Clinical Trials Finder

Conditions: Fibrolamellar Hepatocellular Carcinoma
Interventions: Durvalumab, DRP-104; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 12 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2033
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Rheumatoid Arthritis
Interventions: peficitinib, methotrexate; Drug
Lead sponsor: Astellas Pharma Inc; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 1
States / cities: Anniston, Alabama

Conditions: Clear Cell Renal Cell Carcinoma
Interventions: X4P-001, Nivolumab; Drug
Lead sponsor: X4 Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 4
States / cities: Washington D.C., District of Columbia • Boston, Massachusetts • Hackensack, New Jersey + 1 more

Conditions: Multiple Myeloma
Interventions: Linvoseltamab, Daratumumab, Carfilzomib, Lenalidomide, Bortezomib, Pomalidomide, Isatuximab, Fianlimab, Cemiplimab, Nirogacestat, Cevostamab; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 317 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2032
U.S. locations: 13
States / cities: La Jolla, California • Atlanta, Georgia • Indianapolis, Indiana + 9 more

Conditions: Gastrointestinal Neoplasms, Gastrointestinal Stromal Tumor (GIST), Digestive System Disease, Gastrointestinal Diseases, Metastatic Cancer
Interventions: IDRX-42; Drug
Lead sponsor: IDRX, Inc., a wholly owned subsidiary of GSK, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 276 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 8
States / cities: Miami, Florida • Chicago, Illinois • Boston, Massachusetts + 5 more

Conditions: HIV Infection
Interventions: PGT121 3mg/kg IV, PGT121 10mg/kg IV, PGT121 30mg/kg IV, PGT121 3mg/kg SC, Placebo (0.9% Sodium Chloride Injection USP (Saline)); Biological
Lead sponsor: International AIDS Vaccine Initiative; Network
Eligibility: 18 Years to 65 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Plague
Interventions: Alhydrogel, rF1 and rV protein antigens; Biological
Lead sponsor: PharmAthene UK Limited; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 123 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2007
U.S. locations: 9
States / cities: Huntsville, Alabama • Washington D.C., District of Columbia • Gainesville, Florida + 6 more

Conditions: Advanced or Metastatic Solid Tumor
Interventions: PLN-101095, Pembrolizumab; Drug
Lead sponsor: Pliant Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2030
U.S. locations: 16
States / cities: New Haven, Connecticut • Atlanta, Georgia • Grand Rapids, Michigan + 11 more

Conditions: Advanced Cancer, Lung Cancer, Head and Neck Cancer, Melanoma
Interventions: EOS-448, pembrolizumab, inupadenant, Dostarlimab, SOC chemotherapies; Drug
Lead sponsor: iTeos Belgium SA; Industry
Eligibility: 18 Years and older
Enrollment: 153 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 2
States / cities: San Diego, California • Bergen, New Jersey

Conditions: Neoplasms
Interventions: Ami-LC-MD, Ami-LC, Ami-HC, Ami-HC-CF; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 158 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 5
States / cities: West Hollywood, California • Indianapolis, Indiana • New York, New York + 2 more

Conditions: Non-Hodgkin Lymphoma, B-cell Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Interventions: Azer-cel, Fludarabine, Cyclophosphamide, IL-2, Ibrutinib, Acalabrutinib, Zanubrutinib, or Pirtobrutinib; Biological · Drug
Lead sponsor: Imugene Limited; Industry
Eligibility: 18 Years and older
Enrollment: 135 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 10
States / cities: Tampa, Florida • Atlanta, Georgia • Baltimore, Maryland + 6 more

Conditions: Heterotopic Ossification (HO)
Interventions: Andecaliximab; Drug
Lead sponsor: Ashibio Inc; Industry
Eligibility: 18 Years to 89 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Cocaine Dependence
Interventions: Clavulanic Acid, Placebo; Drug · Other
Lead sponsor: Temple University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Breast Cancer, Breast Neoplasms
Interventions: Disitamab vedotin; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 128
States / cities: Daphne, Alabama • Foley, Alabama • Mobile, Alabama + 103 more

Conditions: Non-Hodgkin's Lymphoma
Interventions: blinatumomab; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 3
States / cities: Duarte, California • Chicago, Illinois • Hackensack, New Jersey

Conditions: Melanoma, Glioma, Thyroid Cancer, Non-Small Cell Lung Cancer, Malignant Neoplasms, Brain Neoplasms, Advanced or Metastatic Solid Tumors, HGG, LGG, Low Grade Glioma, High Grade Glioma, Differentiated Thyroid Cancer, NSCLC (Non-small Cell Lung Cancer)
Interventions: PF-07799544, PF-07799933; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 16 Years and older
Enrollment: 148 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 44
States / cities: Birmingham, Alabama • Fayetteville, Arkansas • Rogers, Arkansas + 22 more

Conditions: Heterozygous Familial Hypercholesterolemia, Premature Coronary Heart Disease
Interventions: VERVE-102; Drug
Lead sponsor: Verve Therapeutics, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 10
States / cities: Dothan, Alabama • Pomona, California • Boca Raton, Florida + 7 more

Conditions: Myeloid Malignancy, Acute Myeloid Leukemia
Interventions: Venetoclax, Decitabine; Drug
Lead sponsor: Benjamin Tomlinson; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 2
States / cities: Cleveland, Ohio

Conditions: Advanced or Metastatic Breast Cancer, Triple Negative Breast Cancer
Interventions: Dinaciclib, Pembrolizumab; Drug
Lead sponsor: Jo Chien; Other
Eligibility: 18 Years to 85 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Breast Cancer, Breast Carcinoma, Malignant Neoplasm of Breast
Interventions: Mammaglobin-A DNA Vaccine, Optional biopsy; Biological · Procedure
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older · Female only
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2028
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Asthma
Interventions: Anti-Asthma Herbal Medical Intervention (ASHMI); Drug
Lead sponsor: Xiu-Min Li; Other
Eligibility: 18 Years to 55 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: New York, New York

Conditions: Fatty Acid Oxidation Disorders
Interventions: Low Dose REN001, High Dose REN001; Drug
Lead sponsor: Reneo Pharma Ltd; Industry
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 5
States / cities: Aurora, Colorado • Portland, Oregon • Pittsburgh, Pennsylvania + 2 more

Conditions: Ulcerative Colitis
Interventions: Microbiota suspension, Microbiota capsule, Placebo suspension, Placebo capsule; Drug
Lead sponsor: Ferring Pharmaceuticals; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 10
States / cities: North Little Rock, Arkansas • Hamden, Connecticut • Inverness, Florida + 7 more

Conditions: Human Immunodeficiency Virus (HIV)
Interventions: Budigalimab, Placebo; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 8
States / cities: Bakersfield, California • Los Angeles, California • San Francisco, California + 5 more

Search by objective public record fields.

DRP-104 (Glutamine Antagonist) in Combination With Durvalumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC)

A Drug Interaction Study to Evaluate the Pharmacokinetics of ASP015K and Methotrexate in Patients With Rheumatoid Arthritis

Addition of X4P-001 to Nivolumab Treatment in Participants With Renal Cell Carcinoma

A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments

First-in-human Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors

Safety, PK and Antiviral Activity of PGT121 Monoclonal Antibody in HIV-uninfected and HIV-infected Adults

One Year Study to Evaluate Three Different Adjuvanted Doses of the Recombinant Plague Vaccine (rF1 and rV Antigens)

A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors

Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors

A Study of Amivantamab Subcutaneous (SC) Administration for the Treatment of Advanced Solid Malignancies

Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)

A Study of Andecaliximab in People With Spinal Cord Injury at Risk for Bone Growth Outside of the Normal Skeleton.

Pharmaco-Magnetic Resonance Spectroscopy (MRS) Study of Clavulanic Acid

A Study of Disitamab Vedotin in Adults With HER2 Expressing Advanced Breast Cancer

A Phase 1b Open-Label Study Investigating the Safety and Pharmacokinetics of Administration of Subcutaneous Blinatumomab for the Treatment of Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma

A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors

A Study of VERVE-102 in Patients With Familial Hypercholesterolemia or Premature Coronary Artery Disease

Decitabine and Venetoclax Treatment as Maintenance Therapy in Patients Post Allograft Stem Cell Transplant

Phase 1b Trial of Dinaciclib With Pembrolizumab for Advanced Breast Cancer

Safety and Immune Response to a Mammaglobin-A DNA Vaccine In Breast Cancer Patients Undergoing Neoadjuvant Endocrine Therapy

Safety Study of Chinese Herbal Therapy to Treat Asthma

A Phase 1b Study of the Safety of REN001 in Patients With Fatty Acid Oxidation Disorders

A Phase 1b Proof-of-concept Trial Exploring the Effects of FE 999322 and FE 999324 in Adults With Mild to Moderate Ulcerative Colitis

Study to Evaluate the Safety and How the Body Handles a Single Dose of Subcutaneous (SC) and Intravenous (IV) Budigalimab in Adult Participants Living With Human Immunodeficiency Virus (HIV)